Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.56 |
| ▸ | PKM | P14618 | 4/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24152814 | 0.88 | ATM (0.64) | PKMGAACA9SMYD3IDO1 | |
| SCHEMBL4907229 | 0.88 | POLB (0.60) | PKMGAASMYD3POLBIDO1 | |
| SCHEMBL5843373 | 0.88 | SMYD3 (0.53) | PKMGAASMYD3POLBIDO1 | |
| SCHEMBL24152535 | 0.87 | GAA (0.55) | PKMGAASMYD3IDO1ATM | |
| SCHEMBL24153272 | 0.87 | PKM (0.54) | PKMGAASMYD3POLBIDO1 | |
| SCHEMBL24152387 | 0.85 | SMYD3 (0.49) | MAOBPKMGAASMYD3IDO1 | |
| SCHEMBL24152389 | 0.85 | LMNA (0.63) | PKMGAAMAPTLMNACYP19A1 | |
| SCHEMBL24152349 | 0.85 | SMYD3 (0.50) | PKMSMYD3POLBIDO1MAPT | |
| SCHEMBL688480 | 0.81 | PKM (0.79) | PKMGAAPOLBIDO1MAPT | |
| SCHEMBL3135008 | 0.81 | MAOB (0.60) | MAOBPKMGAASMYD3IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147586-A1 | Indolinone derivatives as protein kinase/phosphatase inhibitors | SUGEN, INC. | 2004-07-29 | — | — | US | claimed |
| EP-1294688-A2 | INDOLINONE DERIVATIVES AS PROTEIN KINASE/PHOSPHATASE INHIBITORS | Sugen, Inc. (US) | 2003-03-26 | — | — | EP | claimed |
| EP-0657431-B1 | 4-Phenyl-3-substituted 1,4-dihydropyridine esters with cerebral activity | BAYER AG (DE) | 2003-02-19 | — | — | EP | claimed |
| US-20020052369-A1 | Indolinone derivatives as protein kinase/phosphatase inhibitors | SUGEN, INC. | 2002-05-02 | — | — | US | claimed |
| WO-2001094312-A2 | INDOLINONE DERIVATIVES AS PROTEIN KINASE/PHOSPHATASE INHIBITORS | SUGEN, INC. (US) | 2001-12-13 | — | — | WO | claimed |
| US-7071332-B2 | Indolinone derivatives as protein kinase/phosphatase inhibitors | SUGEN, INC. (US) | 2006-07-04 | — | — | US | disclosed |
| US-20040147586-A1 | Indolinone derivatives as protein kinase/phosphatase inhibitors | SUGEN, INC. | 2004-07-29 | — | — | US | disclosed |
| US-6706709-B2 | TREATING, FOR EXAMPLE, PROLIFERATIVE DISORDERS INCLUDING CANCER | SUGEN, INC. | 2004-03-16 | — | — | US | disclosed |
| EP-1294688-A2 | INDOLINONE DERIVATIVES AS PROTEIN KINASE/PHOSPHATASE INHIBITORS | Sugen, Inc. (US) | 2003-03-26 | — | — | EP | disclosed |
| US-20020052369-A1 | Indolinone derivatives as protein kinase/phosphatase inhibitors | SUGEN, INC. | 2002-05-02 | — | — | US | disclosed |
| WO-2001094312-A2 | INDOLINONE DERIVATIVES AS PROTEIN KINASE/PHOSPHATASE INHIBITORS | SUGEN, INC. (US) | 2001-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147586-A1 | Indolinone derivatives as protein kinase/phosphatase inhibitors | PHKA1, PHKA2, PDPK1 | MAOB 840/4885PKM 246/4885GAA 714/4885 |
| US-20020052369-A1 | Indolinone derivatives as protein kinase/phosphatase inhibitors | PHKA1, PHKA2, PDPK1 | MAOB 840/4885PKM 246/4885GAA 714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.